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Atrial fibrillation (AF) is a common arrhythmia. Application of metabolomic approaches,
which may identify novel pathways and biomarkers of disease risk, to a longitudinal epide-
miologic study of AF has been limited.
Methods
We determined the prospective association of 118 serum metabolites identified through
untargeted metabolomics profiling with the incidence of newly-diagnosed AF in 1919 Afri-
can-American men and women from the Atherosclerosis Risk in Communities study without
AF at baseline (1987–1989). Incident AF cases through 2011 were ascertained from study
electrocardiograms, hospital discharge codes, and death certificates.
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Data Availability Statement: Study participants did
not consent to have their data publicly available and
freely accessible and, therefore, we cannot make
share publicly the data. However, the data underlying
our work can be obtained through two mechanisms.
First, interested investigators can contact the ARIC
Coordinating Center at the University of North
Carolina – Chapel Hill. Details about the procedures
for data request can be found in the following
website: http://www2.cscc.unc.edu/aric/distribution-
agreements. Second, most ARIC data can be also
obtained from BioLINCC, a repository maintained by
Results
During a median follow-up of 22 years, we identified 183 incident AF cases. In Cox propor-
tional hazards models adjusted for age, sex, smoking, body mass index, systolic blood
pressure, use of antihypertensive medication, diabetes, prevalent heart failure, prevalent
coronary heart disease, and kidney function, two conjugated bile acids (glycolithocholate
sulfate and glycocholenate sulfate) were significantly associated with AF risk after correct-
ing for multiple comparisons (p<0.0004). Multivariable-adjusted hazard ratios (95% confi-
dence intervals) of AF were 1.22 (1.12–1.32) for glycolithocholate sulfate and 1.22 (1.10–
1.35) for glycocholenate sulfate per 1-standard deviation higher levels. Associations were
not appreciably different after additional adjustment for alcohol consumption or concentra-
tions of circulating albumin and liver enzymes.
Conclusion
We found an association of higher levels of two bile acids with an increased risk of AF, point-
ing to a potential novel pathway in AF pathogenesis. Replication of results in independent
studies is warranted.
Introduction
Atrial fibrillation (AF) is a common cardiac arrhythmia associated with increased mortality
and an elevated risk of stroke, heart failure, myocardial infarction, and dementia.[1] The last
two decades have seen major advances in our understanding of the pathophysiology of AF;
however, key knowledge gaps remain.[2] Identification of novel biomarkers of AF risk could
shed new light into relevant biological pathways and open new avenues for development of
preventive and therapeutic strategies.[3] In this regard, large-scale, high-throughput “omics”
techniques, such as genomics, epigenomics, transcriptomics, proteomics, and metabolomics,
offer a unique opportunity to discover new mechanisms and to refine our comprehension of
established etiopathogenic pathways.[4]
The application of metabolomics—the systematic study of small molecules in a particular
tissue—to research on cardiac arrhythmias, specifically AF, has been limited. Published studies
have examined the metabolomic profile of atrial tissue from AF patients or from a canine
model of AF.[5, 6] These studies found changes in molecules involved in energy metabolism
compared to AF-free controls. However, no prospective assessments of metabolomic profiling
with risk of AF have been previously published. To address this gap, we explored the associa-
tion of molecules identified through untargeted metabolomics with risk of newly-diagnosed
AF in a subset of participants of the Atherosclerosis Risk in Communities (ARIC) study.
Methods
Study sample
The ARIC study is a prospective cohort originally designed to assess risk factors for cardiovas-
cular disease in the general population. A total of 15,792 men and women age 45–64 years old
were recruited from four communities (Forsyth County, North Carolina; Jackson, Mississippi;
northwest suburbs of Minneapolis, Minnesota; and Washington County, Maryland) in 1987–
89. Participants were mostly white in the Minneapolis and Washington County sites, white
and African-American in Forsyth County, while only African-American individuals were
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recruited in Jackson. Study details have been published elsewhere.[7] After the baseline exami-
nation, participants were invited for four follow-up visits in 1990–92, 1993–95, 1996–98, and
2011–13. For the present analysis, we included 1919 African-American participants from the
Jackson site examined at the baseline visit with metabolomics profiling and without evidence
of AF at recruitment. The ARIC study has been approved by the Institutional Review Board at
the University of Minnesota, Johns Hopkins University, Wake Forest University, University of
North Carolina, University of Texas Health Sciences Center at Houston, and University of Mis-
sissippi Medical Center. Participants provided written informed consent.
Metabolomic profiling
As previously described in detail in the context of a study assessing metabolomic predictors of
heart failure [8], metabolomic profiles were performed in 2010 in serum samples obtained
from a subset of 1977 African Americans in the Jackson field center. These samples had been
kept at -80°C since their collection in 1987–89 and were assayed with an untargeted, gas chro-
matography/mass spectrometry and liquid chromatography/mass spectrometry–based meta-
bolomic quantification protocol by Metabolon, Inc. (Durham, North Carolina). This approach
identified and quantified named compounds with known chemical identities as well as
unnamed compounds without current chemical standards. For the present analysis, we consid-
ered 118 named compounds with adequate medium-term reliability (defined as a reliability
coefficient0.6 in repeat samples obtained 4–6 weeks apart in 60 individuals)[9] and80% of
missing values or below the limit of detection.
Ascertainment of AF
A thorough description of AF ascertainment in the ARIC study has been previously published.
[10, 11] Briefly, cases of AF were identified from three sources: electrocardiograms (ECG) at
the study examinations, hospital discharge codes, and death certificates. At all examinations,
participants underwent a standard 12-lead ECG with MAC PC ECG machines (Marquette
Electronics, Milwaukee, WI). Digital ECG information was transferred to the ARIC ECG Read-
ing Center located at the Epidemiological Cardiology Research Center, Wake Forest School of
Medicine, Winston Salem, NC, where it was automatically processed using GE Marquette
12-SL program (GE Marquette, Milwaukee, WI). All automatically detected AF cases were
reviewed by an experienced cardiologist. Hospitalizations during follow-up are identified
through annual follow-up calls (response rate>90%) and surveillance of local hospitals, and
hospitalization discharge codes are recorded. AF was considered present if ICD-9-CM codes
427.31 or 427.32 were present in a hospitalization in any position not accompanied by a proce-
dure code for open cardiac surgery. This approach for case ascertainment has demonstrated
adequate validity in the ARIC cohort and other studies.[10, 12] Finally, AF was considered
present if the death certificate included ICD-9 code 427.3 or ICD-10 code I48.
Assessment of other covariates
At baseline, information on age, sex, race, and smoking status was self-reported. Alcohol con-
sumption was ascertained by an interviewer-administered questionnaire. Height and weight
were measured with the participant lightly dressed. Body mass index was calculated as weight
in kilograms divided by height in meters squared. Sitting blood pressure was measured three
times using a random-zero sphygmomanometer after five minutes of rest, and the second and
third measurements were averaged. Diabetes was defined as a fasting blood glucose126 mg/
dL, non–fasting blood glucose200 mg/dL, a self-reported physician diagnosis of diabetes, or
current use of antidiabetic medication. Estimated glomerular filtration rate (eGFRCKD-EPI) was
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calculated from serum creatinine using the CKD-EPI equation.[13] Serum albumin was mea-
sured with a Coulter DACOS (Coulter Diagnostics) using Coulter’s bromcresol green colori-
metric assay. Liver enzymes (aspartate aminotransferase, alanine aminotransferase, gamma-
glutamyl transpeptidase) were measured in serum samples collected at visit 2 (1990–1992)
using Roche reagents on the Roche Modular P800 Chemistry analyzer (Roche Diagnostics Cor-
poration). Prevalent heart failure was defined using the Gothenburg criteria,[14] while preva-
lent coronary heart disease was considered present if the participant self-reported a history of
myocardial infarction, coronary bypass surgery, or coronary angioplasty, or had evidence of a
previous myocardial infarction by ECG at the baseline visit.
Statistical analysis
The association of each metabolite with newly-diagnosed AF was evaluated using Cox propor-
tional hazards regression. Time to follow-up was defined as the time between the baseline exami-
nation and the incidence of AF, death, loss to follow-up, or December 31, 2011, whichever
occurred first. Metabolites with<50%missing or below the detection limit values were mean cen-
tered and modeled as continuous variables in standard deviation units; missing values for this
group were imputed using the lowest detectable value in the study sample. Metabolites with 50–
80%missing or below the detection limit values were modeled as an ordinal variable with 3 levels:
missing/below the detection limit, detected below the median, and detected equal or above the
median. Models were initially adjusted for age and sex. A second model additionally adjusted for
smoking status (current vs former/never), body mass index, systolic blood pressure, hypertension
medications, diabetes, prevalent heart failure, and prevalent coronary heart disease. Finally, a third
model added eGFRCKD-EPI to the previously listed covariates. Significance tests were corrected
using the Dubey/Armitage-Parmar algorithm, a modified Bonferroni procedure.[15] Applying
this method to the metabolomics data, two-tailed p-values<0.0004 were considered statistically
significant. Because the two metabolites significantly associated with AF risk in our analysis may
be considered markers of liver function or damage (see below), we conducted a sensitivity analysis
further adjusting for baseline serum albumin, baseline alcohol consumption (in grams/week), and
liver enzymes (aspartate aminotransferase, alanine aminotransferase, gamma-glutamyl transpepti-
dase) measured at visit 2. Also, given the role of bile acids in cholesterol metabolism and the
potential link of blood lipids with AF incidence [16, 17], we conducted an analysis adjusting for
baseline serum LDL cholesterol, HDL cholesterol and triglycerides. Additionally, we performed
sex-specific analysis for the two metabolites significantly associated with AF risk.
The proportional hazards assumption was assessed with Schoenfeld residuals and including
interaction terms between time and the corresponding metabolite in the regression model. We
explored the shape of the association between the significant metabolites and AF risk by model-
ing the metabolite as restricted cubic splines with knots at the 5th, 27.5th, 50th, 72.5th, and 95th
percentiles, as recommended by Harrell.[18] Finally, to determine the joint association of the two
significant metabolites with AF risk, we conducted two additional analyses. First, we ran a multi-
variable Cox model including both metabolites simultaneously. Second, we categorized the study
participants by quintiles of the two metabolites and created a new variable as the sum of the quin-
tiles rank (range 2–10); this variable was modeled both as a continuous and a categorical variable
(with individuals in the bottom quintile of both metabolites as the reference group).
All analyses were conducted using SAS version 9.2 or 9.3 (SAS Institute, Inc., Cary, NC).
Results
Of 1977 participants with available metabolomics profiling, 58 were excluded because they had
prevalent AF or did not have a baseline electrocardiogram, leaving 1919 eligible individuals.
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During a median follow-up of 22 years, 183 incident cases of AF were identified (incidence
rate: 5.0 per 1000 person-years). Table 1 reports selected baseline characteristics by AF status
during follow-up. Compared to those without diagnosed AF during follow-up, those who
developed AF were slightly older, more likely to be male and current smokers, had higher body
mass index and systolic blood pressure and higher prevalence of diabetes and prevalent cardio-
vascular diseases.
In models adjusted for age and sex, 8 metabolites were significantly associated with AF risk
(p<0.0004) (Table 2). After additional adjustment for several AF risk factors, two metabolites,
the bile acids glycolithocholate sulfate and glycocholenate sulfate, remained significantly asso-
ciated. The hazard ratios (HR) and 95% confidence interval (CI) of AF per 1-standard devia-
tion higher levels were 1.22, 95%CI 1.12–1.32 for glycolithocholate sulfate, and 1.22, 95%CI
1.10–1.35 for glycocholenate sulfate. Further adjustment for kidney function did not change
the associations (Table 2). When modeled as restricted cubic splines, both glycolithocholate
Table 1. Selected baseline characteristics by atrial fibrillation (AF) status during follow-up in a sub-
sample (N = 1919) of participants from the Atherosclerosis Risk in Communities (ARIC) study Jack-
son, Mississippi field center without AF at baseline (1987–1989).
Baseline characteristics* No incident AF Incident AF
N 1736 183
Age, years 53 (6) 56 (6)
Women, % 65.4 56.8
Body mass index, kg/m2 29.5 (6.0) 30.9 (6.2)
Current smokers, % 28.1 35.0
Systolic blood pressure, mmHg 127 (21) 137 (24)
Anti-hypertensive medication, % 36.3 51.4
Diabetes, % 14.6 29.5
eGFRCKD-EPI, mL/min/1.73 m
2 113 (18) 109 (20)
Prevalent heart failure, % 4.4 8.7
Prevalent coronary heart disease, % 3.2 8.7
*Values correspond to means (standard deviation) or percentages
eGFRCKD-EPI: estimated glomerular filtration rate
doi:10.1371/journal.pone.0142610.t001
Table 2. Association of individual metabolites with incidence of atrial fibrillation, ARIC subsample, 1987–2011. Only metabolites that were statisti-
cally significant at p<0.0004 in the age- and sex-adjusted model are shown.
Metabolite Model 1 Model 2 Model 3
HR (95%CI) P-value HR (95%CI) P-value HR (95%CI) P-value
Glycolithocholate sulfate 1.23 (1.15, 1.32) 7.4×10−9 1.22 (1.12, 1.32) 1.8×10−6 1.22 (1.13, 1.32) 1.2×10−6
Glycocholenate sulfate 1.29 (1.18, 1.40) 1.3×10−8 1.22 (1.10, 1.35) 0.0002 1.22 (1.10, 1.36) 0.0001
Erythritol 1.32 (1.19, 1.47) 2.1×10−7 1.22 (1.08, 1.38) 0.002 1.23 (1.06, 1.42) 0.005
Hexanoylcarnitine 1.19 (1.08, 1.30) 0.0003 1.14 (1.03, 1.27) 0.01 1.14 (1.03, 1.27) 0.01
Mannose 1.32 (1.21, 1.45) 2.3×10−9 1.19 (1.03, 1.37) 0.02 1.20 (1.04, 1.38) 0.01
Glucose 1.37 (1.23, 1.52) 4.0×10−9 1.19 (1.03, 1.39) 0.02 1.20 (1.03, 1.39) 0.02
o-cresol sulfate 1.23 (1.10, 1.38) 0.0003 1.11 (0.96, 1.28) 0.17 1.09 (0.95, 1.27) 0.22
Cotinine 1.38 (1.16, 1.65) 0.0004 1.08 (0.83, 1.41) 0.56 1.08 (0.83, 1.41) 0.57
Model 1: Cox proportional hazards model adjusted for age and sex. Model 2: As Model 1, additionally adjusted for smoking, body mass index, systolic
blood pressure, use of antihypertensive medications, diabetes mellitus, prevalent heart failure, and prevalent coronary heart disease. Model 3: As Model
2, additionally adjusted for eGFRCKD-EPI
doi:10.1371/journal.pone.0142610.t002
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sulfate and glycocholenate sulfate showed roughly linear associations with the HR for AF (Fig
1). Complete results for the 118 metabolites are provided as a supplementary file (S1 Table).
We did not find any evidence of violation of the proportional hazards assumption.
We performed some additional analyses. Since sulfated bile acids have been described as
potential markers of hepatobiliary diseases, we performed an analysis adjusting for baseline
serum albumin, alcohol consumption, and liver enzymes measured at visit 2. After these addi-
tional adjustments, both glycolithocholate sulfate and glycocholenate sulfate remained associ-
ated with AF incidence (HR, 95%CI: 1.18, 1.09–1.29 and 1.23, 1.10–1.36, respectively).
Likewise, both metabolites showed similar associations with AF incidence after adjustment for
baseline serum LDL cholesterol, HDL cholesterol and triglycerides (HR, 95%CI: 1.17, 1.08–
1.27 for glycolithocholate sulfate and 1.18, 1.07–1.30 for glycocholenate sulfate). We also
explored the association of both metabolites with incidence of AF in men and women sepa-
rately. No differences were observed in the association of glycocholenate sulfate with AF inci-
dence by sex; however, glycolithocolate sulfate was more strongly associated with AF incidence
in men than in women (p for interaction< 0.001) (S2 Table).
Finally, we assessed whether associations of both metabolites with AF risk were independent
of each other. The two bile acids were moderately correlated (r = 0.45). When included simul-
taneously in a multivariable Cox model, the association of both metabolites with AF incidence
became weaker and remained significant at the traditional p = 0.05 level only for glycolithocho-
late sulfate, but not for glycocholenate sulfate (HR 1.16, 95%CI 1.02–1.31, p = 0.02 for glyco-
lithocholate sulfate and 1.09, 95%CI 0.94–1.25, p = 0.25 for glycocholenate sulfate). When the
circulating levels of both metabolites were jointly modeled as the sum of their quintiles (rank 2
to 10), the association became stronger: the HR (95%CI) of AF among participants in the top
quintile of both bile acids, compared to those in the bottom quintiles, was 2.99 (1.12–7.99), and
the p-value for the sum of quintiles modeled as a continuous variable was 0.003.
Fig 1. Association of concentrations of glycolithocholate sulfate (A, left panel) and glycocholenate sulfate (B, right panel) with incidence of atrial
fibrillation presented as hazard ratio (HR; solid line) and 95% confidence intervals (CI; shaded area).Results from Cox proportional hazards model
with metabolites modeled using restricted cubic splines (knots at 5th, 27.5th, 50th, 72.5th, and 95th percentiles), adjusted for age, sex, body mass index,
smoking, diabetes, systolic blood pressure, use of antihypertensive medication, prevalent coronary heart disease, prevalent heart failure, and eGFRCKD-EPI.
Median value of the metabolite was considered the reference (HR = 1). The histograms represent the frequency distribution of both metabolites in the study
sample. The red dots indicate the position of the knots used in the restricted cubic splines. Atherosclerosis Risk in Communities Study subsample, 1990–
2011. eGFRCKD-EPI: CKD-EPI creatinine-based estimated glomerular filtration rate.
doi:10.1371/journal.pone.0142610.g001
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Discussion
In this systematic assessment of circulating metabolites and AF risk, we found that increased
levels of two conjugated bile acids, glycolithocholate sulfate and glycocholenate sulfate, were
associated with increased incidence of AF. This association was independent of other risk fac-
tors for AF, including kidney function, and of alcohol consumption and markers of liver dam-
age and function.
To date, the use of metabolomics in the study of AF has been limited to cross-sectional stud-
ies. Mayr and colleagues used a combined metabolomic and proteomic approach in human
atrial tissue from patients with AF and controls in sinus rhythm [5]. Using high-resolution pro-
ton nuclear magnetic resonance spectroscopy, the authors found that levels of beta-hydroxybu-
tyrate, involved in ketone body metabolism, ketogenic amino acids, and glycine were elevated
in cardiac tissue from patients with persistent AF. Also employing a combined metabolomics
and proteomic approach, De Souza and colleagues studied left-atrial cardiomyocytes of ven-
tricular-tachypaced dogs, an animal model of heart failure-induced AF, and sham controls [6].
Observed metabolic changes suggested increased metabolic stress paired with inefficient energy
utilization, and a shift from glycolysis to ketoacid metabolism. In contrast to our analysis of the
ARIC cohort, these two studies focused on metabolomics of AF-affected cardiac tissue, not
directly addressing the association of circulating metabolites with the risk of developing AF.
The two molecules associated with AF risk in our study are glycine-conjugated bile acids
that have also undergone sulfation. Specifically, glycolithocholate sulfate is derived from gly-
cine-conjugated lithocholic acid, a secondary bile acid synthesized by intestinal bacteria from
chenodeoxycholic acid, a primary bile acid excreted by the liver. Lithocholic acid in abnormally
high concentrations can be cytotoxic; sulfation reduces its toxic effects through increased
hydrophilicity and enhanced fecal and urinary excretion [19]. High levels of glycolithocolate
sulfate in urine have been associated with presence of chronic hepatic disease, suggesting a
potential role as marker of liver damage [20]. Glycocholenate sulfate, on the other hand, is pos-
sibly synthesized from glycine-amidation and sulfation of 3-beta-hydroxy-5-cholenoic acid
(also known as cholenate). Previous literature has described elevations of 3-beta-hydroxy-
5-cholenoic acid in patients with liver disease, particularly in those with primary biliary cirrho-
sis [21], a condition characterized by progressive inflammatory destruction of the bile ducts,
leading to cirrhosis. The untargeted metabolomics assessment measured other bile acids in
serum, including glycocholate, glycodeoxycholate, and ursodeoxycholate, but none of these
were significantly associated with AF risk after correction for multiple comparisons.
The mechanism responsible for the association of higher levels of bile acids with risk of AF
is unclear. Both glycolithocolate sulfate and glycocholenate sulfate may be elevated in the con-
text of liver disease. We and others have shown that higher circulating levels of liver enzymes,
markers of liver damage, are associated with an increased risk of AF [22, 23]. In the present
analysis, however, the association of the two bile acids with higher AF risk was independent of
markers of liver damage and function, pointing to different pathways underlying this associa-
tion. Limited previous evidence has linked bile acids with the occurrence of arrhythmias.
Experiments in rat ventricular muscle have demonstrated negative inotropic effects of high lev-
els of bile acids [24], and studies in neonatal rat cardiomyocyte cultures have also demonstrated
that taurine-conjugated bile acids cause bradycardia and loss of synchronous beating [25].
Moreover, intrahepatic cholestasis of pregnancy, a disorder characterized by elevated maternal
serum bile acids, has been linked to presence of fetal cardiac arrhythmias [26]. Recently, Rainer
and colleagues explored the potential arrhythmogenic effects of bile acids in the adult human
heart [27]. Their studies found that increasing concentrations of taurine- and glycine-conju-
gated bile acids caused increased occurrence of arrhythmic extra contractions in myocardial
Metabolomics in Atrial Fibrillation
PLOS ONE | DOI:10.1371/journal.pone.0142610 November 6, 2015 7 / 10
tissue extracted from the right atrium of adult patients undergoing heart surgery. They also
found higher concentrations of non-ursodeoxycholate bile acids in patients with AF compared
with controls in sinus rhythm [27]. These findings, together with growing evidence of the sys-
temic metabolic effects of circulating bile acids through activation of farnesoid X receptor [28],
and the effect that the gut microbiota (responsible for secondary bile acids synthesis) has in
cardiometabolic health [29], suggest that future research should pay additional attention to the
role of bile acids in cardiac arrhythmogenesis.
Strengths of our study include the well-characterized cohort with excellent follow-up and
availability of rigorous information on potential confounders. Some limitations need to be
mentioned. First, our method of AF ascertainment probably missed asymptomatic cases and
those managed exclusively in the outpatient setting. Previous work, however, has shown the
high specificity and validity of AF ascertainment using hospitalization discharge codes in the
ARIC cohort and other epidemiologic studies [10, 12]. Second, we only had single metabolomic
assessments and this may be insufficient to characterize long-term levels of these metabolites.
Nonetheless, as described in the methods, we only considered in our analysis metabolites with
adequate medium-term reliability [9]. Third, we do not have direct evidence of the stability of
the metabolite profile over the more than 20 years that the samples remained in storage.
Finally, an additional limitation includes the unavailability of a replication sample. Although
not a limitation, restriction of our study to African Americans makes uncertain the generaliz-
ability of our results to other racial groups.
Conclusions
We have identified a novel association of two secondary bile acids with the incidence of AF.
Replication of these results in additional studies is critical. If our observations are replicated,
additional research should address the potential pathways linking bile acid metabolism with
the etiopathogenesis of AF.
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